OBJECTIVE: To assess the effects of estro-progestin supplementation on ghrelin-mediated GH release, we studied the consequence of ghrelin or saline injection before and after 60 days of hormone therapy or placebo administration in postmenopausal subjects. DESIGN: A prospective double blind, placebo-controlled, and parallel cohort study. SETTING:Catholic University of Sacred Heart, Operative Division of Endocrinological Gynecology. PATIENT(S): Eighteen postmenopausal women participated in the study. INTERVENTION(S): Ten women were randomized to receive estro-progestin treatment (2 mg of hemihydrate E(2) and 10 mg of dydrogesterone in a continuous sequential regimen); eight women were treated with placebo. All patients underwent in a randomized order a ghrelin test (1 microg/kg IV bolus) or a saline infusion (2-mL IV bolus) on two different days, before and after 60 days of treatment. MAIN OUTCOME MEASURE(S): Basal hormonal assays, including ghrelin basal levels. The GH levels were measured at baseline and after 15, 30, 60, 90 minutes of ghrelin or saline injection. RESULT(S): The acute ghrelin injection released a notable GH secretion in all postmenopausal women. After estro-progestin therapy the ghrelin-stimulated GH response was significantly higher than before treatment. In particular, the percent increase of ghrelin GH-releasing effect, expressed as incremental area under the curve (AUCi-GH) was more than 50% after hormone therapy. CONCLUSION(S): In postmenopausal women estro-progestin treatment clearly influenced the ghrelin-stimulated GH secretion.
RCT Entities:
OBJECTIVE: To assess the effects of estro-progestin supplementation on ghrelin-mediated GH release, we studied the consequence of ghrelin or saline injection before and after 60 days of hormone therapy or placebo administration in postmenopausal subjects. DESIGN: A prospective double blind, placebo-controlled, and parallel cohort study. SETTING: Catholic University of Sacred Heart, Operative Division of Endocrinological Gynecology. PATIENT(S): Eighteen postmenopausal women participated in the study. INTERVENTION(S): Ten women were randomized to receive estro-progestin treatment (2 mg of hemihydrate E(2) and 10 mg of dydrogesterone in a continuous sequential regimen); eight women were treated with placebo. All patients underwent in a randomized order a ghrelin test (1 microg/kg IV bolus) or a saline infusion (2-mL IV bolus) on two different days, before and after 60 days of treatment. MAIN OUTCOME MEASURE(S): Basal hormonal assays, including ghrelin basal levels. The GH levels were measured at baseline and after 15, 30, 60, 90 minutes of ghrelin or saline injection. RESULT(S): The acute ghrelin injection released a notable GH secretion in all postmenopausal women. After estro-progestin therapy the ghrelin-stimulated GH response was significantly higher than before treatment. In particular, the percent increase of ghrelin GH-releasing effect, expressed as incremental area under the curve (AUCi-GH) was more than 50% after hormone therapy. CONCLUSION(S): In postmenopausal women estro-progestin treatment clearly influenced the ghrelin-stimulated GH secretion.
Authors: C I Messini; K Dafopoulos; N Chalvatzas; P Georgoulias; G Anifandis; I E Messinis Journal: J Endocrinol Invest Date: 2010-06-04 Impact factor: 4.256
Authors: K Dafopoulos; N Chalvatzas; G Kosmas; A Kallitsaris; S Pournaras; I E Messinis Journal: J Endocrinol Invest Date: 2010-02 Impact factor: 4.256
Authors: Diaa E E Rizk; Hazem A Hassan; Ahmed H Al-Marzouqi; Mohammed Shafiullah; Mohamed A Fahim Journal: Int Urogynecol J Pelvic Floor Dysfunct Date: 2008-05-22
Authors: Christina I Messini; Konstantinos Dafopoulos; Maria Malandri; Panagiotis Georgoulias; George Anifandis; Ioannis E Messinis Journal: Reprod Biol Endocrinol Date: 2013-05-10 Impact factor: 5.211